相关实验视频

Updated: Jan 18, 2026

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

儿童缺血性中风在COVID-19中的机制:系统性审查

Elbert John V Layug^1,2, Almira Doreen Abigail O Apor¹, Rudolf V Kuhn³

¹Department of Neurosciences, College of Medicine and Philippine General Hospital, University of the Philippines Manila, Manila, Philippines.

Frontiers in stroke

|January 16, 2026

概括

COVID-19可能会导致血管病变和凝血问题,导致儿科缺血性中风. 这项对74名儿童的审查表明SARS-CoV-2感染和脑血管事件之间的潜在联系.

科学领域:

神经学神经学
儿科儿科儿科
传染性疾病传染性疾病

背景情况:

冠状病毒疾病2019 (COVID-19) 与成人脑血管和血栓性疾病有关.
关于COVID-19儿童中风的数据有限,因此需要对独特的风险因素和病理机制进行表征.
了解这些机制对于开发有效的管理方案至关重要,以改善儿科中风患者的治疗结果.

研究的目的:

对于COVID-19儿童中风的特征.
了解COVID-19相关的儿科缺血性中风背后的机制.
为改善这一群体的结果提供管理协议的信息.

主要方法:

在主要数据库 (MEDLINE,EMBASE,Web of Science,Google Scholar) 中进行了系统的文献搜索.
关键词包括"儿科缺血性中风"",脑内血栓症"",SARS-CoV-2"和"COVID-19".
提取的数据包括患者人口统计,临床资料,危险因素,神经成像,干预措施和结果.

主要成果:

该审查分析了52篇文章,其中包括74名COVID-19相关中风的儿科患者.
儿科缺血性中风主要是动脉 (82.40%),其中的机制包括血栓友好症 (47.3%) 和血管病变 (27%).
结果各不相同,完全恢复 (13/58),残余赤字 (35/58) 和死亡率 (10/58).

结论:

这些发现支持了SARS-CoV-2可以诱导血管病变和凝血失调的假设,使儿童易患缺血性中风.
这份已发表文献的综合摘要强调了COVID-19背景下的儿科缺血性中风的临床概况和结果.
需要进一步的研究来阐明特定的病理机制和优化治疗策略.

关键词:

在 COVID-19 疫情中,这就是SARS-CoV-2病毒.童年缺血性中风儿童缺血性中风儿科中风儿科中风年轻人的中风.

更多相关视频

Transient Middle Cerebral Artery Occlusion Model of Neonatal Stroke in P10 Rats

Transient Middle Cerebral Artery Occlusion Model of Neonatal Stroke in P10 Rats

Published on: April 21, 2017

A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice

A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice

Published on: June 22, 2022

相关概念视频

Ischemic Heart Disease: Overview

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...

Pharmacokinetics in Pediatric Patients: Drug Metabolism

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...